BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 17851840)

  • 21. [ATRAC therapy].
    Miyazaki Y
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():628-31. PubMed ID: 25831836
    [No Abstract]   [Full Text] [Related]  

  • 22. A case of pancreatitis associated with all-trans-retinoic acid therapy in acute promyelocytic leukemia.
    Abou Chacra L; Ghosn M; Ghayad E; Honein K
    Hematol J; 2001; 2(6):406-7. PubMed ID: 11920282
    [No Abstract]   [Full Text] [Related]  

  • 23. All-trans retinoic acid-induced myositis.
    Kannan K; Khan HA; Jain R; Hussein SS; Dennison D
    Br J Haematol; 2005 Dec; 131(5):560. PubMed ID: 16351631
    [No Abstract]   [Full Text] [Related]  

  • 24. [Acute promyelocytic leukemia associated with hemophagocytic syndrome].
    Jinta M; Arai A; Yamamoto K; Sakashita C; Fukuda T; Miu T; Koyama T; Murakami N; Miura O
    Rinsho Ketsueki; 2007 Apr; 48(4):310-4. PubMed ID: 17515122
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in management of acute promyelocytic leukemia with arsenic trioxide.
    Ma J
    Chin J Integr Med; 2007 Jun; 13(2):92-4. PubMed ID: 17609904
    [No Abstract]   [Full Text] [Related]  

  • 26. Translocation (2;11)(q37;q23) in therapy-related myelodysplastic syndrome after treatment for acute promyelocytic leukemia.
    Snijder S; Mellink CH; van der Lelie H
    Cancer Genet Cytogenet; 2008 Jan; 180(2):149-52. PubMed ID: 18206542
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The expanding role of arsenic in acute promyelocytic leukemia.
    Tallman MS
    Semin Hematol; 2008 Jul; 45(3 Suppl 2):S25-9. PubMed ID: 18760708
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Liposomal daunorubicin (daunosom) in the treatment of recurrent acute promyelocytic leukemia].
    Pivnik AV; Shtroiakovskiĭ DL; Medvedev PV; Moiseeva TN; Shklovskiĭ-Kordi NE; Skorokhod AA
    Ter Arkh; 1999; 71(7):24-7. PubMed ID: 10481863
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinical and biological features of acute promyelocytic leukemia patients developing retinoic acid syndrome during induction treatment with all-trans retinoic acid and idarubicin.
    Breccia M; Latagliata R; Carmosino I; Cannella L; Diverio D; Guarini A; De Propris MS; Petti MC; Avvisati G; Cimino G; Mandelli F; Lo-Coco F
    Haematologica; 2008 Dec; 93(12):1918-20. PubMed ID: 18945746
    [No Abstract]   [Full Text] [Related]  

  • 30. The 'standard of care' in acute promyelocytic leukemia.
    Warrell RP
    Leukemia; 1994; 8 Suppl 2():S56-8; discussion S62. PubMed ID: 7815838
    [No Abstract]   [Full Text] [Related]  

  • 31. Retinoic acid syndrome subsequent to the first dose of all trans retinoic acid.
    Altintaş A; Paşa S; Cil T; Kaplan MA; Ayyildiz O
    J Emerg Med; 2008 Nov; 35(4):456-7. PubMed ID: 18554851
    [No Abstract]   [Full Text] [Related]  

  • 32. Combination brings long-term remission in acute promyelocytic leukemia refractory for both all-trans retinoic acid and arsenic trioxide.
    Sasaki M; Sugimoto K; Isobe Y; Oshimi K
    Eur J Haematol; 2008 Aug; 81(2):160. PubMed ID: 18363868
    [No Abstract]   [Full Text] [Related]  

  • 33. Use of all-trans retinoic acid in combination with arsenic trioxide for remission induction in patients with newly diagnosed acute promyelocytic leukemia and for consolidation/maintenance in CR patients.
    Dai CW; Zhang GS; Shen JK; Zheng WL; Pei MF; Xu YX; Cao YX; Yi Y; Yang JJ; Peng HL; Zhong HY; Li RJ
    Acta Haematol; 2009; 121(1):1-8. PubMed ID: 19246888
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acute colonic pseudo-obstruction (Ogilvie's syndrome) during induction treatment with chemotherapy and all-trans-retinoic acid for acute promyelocytic leukemia.
    Delmer A; Cymbalista F; Bauduer F; Martin A; Rio B; Fenaux P; Marie JP; Zittoun R
    Am J Hematol; 1995 May; 49(1):97-8. PubMed ID: 7741149
    [No Abstract]   [Full Text] [Related]  

  • 35. All-trans retinoic acid--chemotherapy interactions in acute promyelocytic leukaemia.
    Roberts AW; Sheridan WP; Grigg AP
    Aust N Z J Med; 1992 Dec; 22(6):704. PubMed ID: 1489298
    [No Abstract]   [Full Text] [Related]  

  • 36. Could ATRA/Idarubicin treatment of acute promyelocytic leukemia induce the appearance of new clonal cytogenetic abnormalities in patients in complete remission?
    Mallo M; Salido M; Espinet B; Cervera J; Canellas A; Pajuelo JC; Pedro C; Florensa L; Sanz MA; Solé F
    Leuk Res; 2007 Sep; 31(9):1315-7. PubMed ID: 17092559
    [No Abstract]   [Full Text] [Related]  

  • 37. Acute renal failure during ATRA treatment.
    Yarali N; Tavil B; Kara A; Ozkasap S; Tunç B
    Pediatr Hematol Oncol; 2008 Mar; 25(2):115-8. PubMed ID: 18363177
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Current therapy of acute promyelocytic leukemia using vitamin A derivatives].
    Löwenberg B; Budel LM
    Ned Tijdschr Geneeskd; 1993 Apr; 137(16):796-8. PubMed ID: 8487880
    [No Abstract]   [Full Text] [Related]  

  • 39. Avascular necrosis of head of femur in a patient with acute promyelocytic leukemia.
    Abhyankar D; Nair R; Menon H; Kapoor B; Advani S
    Leuk Lymphoma; 2000 May; 37(5-6):635-7. PubMed ID: 11042527
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Severe myopericarditis following induction therapy with idarubicin and transretinoic acid in a patient with acute promyelocytic leukemia.
    Carcelero San Martín E; Riu Viladoms G; Creus Baró N
    Med Clin (Barc); 2018 Jun; 150(12):492-493. PubMed ID: 29196036
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.